Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Figlin

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|February 6, 1997
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancerM Fanucchi, J Glaspy, J Crawford, et al.
Human Gene Therapy|June 2, 2001
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biologyA Belldegrun, C L Tso, A Zisman, et al.
Investigational New Drugs|June 17, 2000
A phase II pilot study of KW-2189 in patients with advanced renal cell carcinomaE J Small, R Figlin, D Petrylak, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1993
A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanomaR P Whitehead, R Figlin, M L Citron, et al.
The Journal of Urology|November 1, 1993
Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinomaA Belldegrun, W Pierce, R Kaboo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2000
Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinomaA Hinkel, C L Tso, B J Gitlitz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 4, 1998
Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinomaP Mulders, C L Tso, S Pang, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinomaG G Steger, M F Gnant, M P Djavanmard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccinesP Mulders, C L Tso, B Gitlitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|February 6, 1997
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancerM Fanucchi, J Glaspy, J Crawford, et al.
Human Gene Therapy|June 2, 2001
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biologyA Belldegrun, C L Tso, A Zisman, et al.
Investigational New Drugs|June 17, 2000
A phase II pilot study of KW-2189 in patients with advanced renal cell carcinomaE J Small, R Figlin, D Petrylak, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1993
A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanomaR P Whitehead, R Figlin, M L Citron, et al.
The Journal of Urology|November 1, 1993
Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinomaA Belldegrun, W Pierce, R Kaboo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2000
Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinomaA Hinkel, C L Tso, B J Gitlitz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 4, 1998
Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinomaP Mulders, C L Tso, S Pang, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinomaG G Steger, M F Gnant, M P Djavanmard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccinesP Mulders, C L Tso, B Gitlitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
Pageof 5